Skip to main content

IPR-803 (C09-1140-379)

Aladdin

Catalog No.
C09-1140-379
Manufacturer No.
I651117-5mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $322.59
List Price: $358.43

IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI) . IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activityIn VitroIPR-803 blocks invasion of breast cancer cells line

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI) . IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activityIn VitroIPR-803 blocks invasion of breast cancer cells line MDA-MB-231, and inhibits matrix metalloproteinase (MMP) breakdown of the extracellular matrix (ECM). ?/nIPR-803 impairs MDA-MB-231 cell adhesion and migration. ?/nIPR-803 induces a concentration-dependent impairment of cell adhesion with an IC 50 of approximately 30 μM. ?/nIPR-803 inhibits MDA-MB-231 cells growth with an IC 50 of 58 μM. ?/nIPR-803 (0-200 μM; 3 days) blocks the invasion of MDA-MB-231 cells, and most of the inhibition of cell invasion is unlikely due to cytotoxicity of the compound. ?/nIPR-803 (1-50 μM; 24 hours) does not have a significant effect on apoptosis or necrosis. ?/nIPR-803 (50 μM; 30 minutes) shows inhibition of MAPK phosphorylation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: MDA-MB-231 cells Concentration: 0 μM, 50 μM, 150 μM, 200 μM Incubation Time: 3 days Result: Displays 90 percent blockage of invasion that is observed at 50 μM.In VivoIPR-803 (200 mg/kg; i.g.; three times a week; for 5 weeks) impairs breast cancer metastasis, but no statistical significance to the differences in body weight between treated and untreated . ?/nIPR-803 has a low oral bioavailability at 4 percent, and remains high concentration even after 10 hours in tumor tissue . ?/nIPR-803 exhibits a half-life (t1/2) of 5 hours . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NSG mice with MDA-MB-231 cells xenograft Dosage: 200 mg/kg Administration: Oral gavage; three times a week; for 5 weeks Result: Impaired metastasis to the lungs. Animal Model: NOD/SCID mice Dosage: 200 mg/kg (Pharmacokinetic Study) Administration: Oral administration Result: t1/2=5 hours.Form:SolidIC50& Target:Ki: 0.2 μM (PPI). Specification: ≥98.0% Molecular Formula: C27H23N3O4 Molecular Weight: 453.49 PubChem CID: 3675673 Isomeric SMILES: C1CCCN(CC1)C2=CC(=C3C4=C(C5=CC=CC=C5C3=O)ON=C24)NC6=CC=CC(=C6)C(=O)O
UPC:
12352209
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
I651117-5mg
CAS:
892243-35-5
Product Size:
5mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.